Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xi'an, China.
Front Endocrinol (Lausanne). 2024 Aug 14;15:1391902. doi: 10.3389/fendo.2024.1391902. eCollection 2024.
In the realm of natural frozen-thawed embryo transfer (FET) cycles, the application of luteal phase support (LPS) is a prevalent practice, primarily due to its beneficial impact on reproductive outcomes. Among the various LPS medications, human chorionic gonadotropin (hCG) is one that exerts its function on both the corpus luteum and the endometrium.
To evaluate the effect of hCG administration as LPS on reproductive outcomes in natural FET cycles.
This study was a retrospective cohort analysis conducted at a tertiary care hospital. It included women who underwent natural FET treatment from January 2018 to December 2022. Participants were divided into the hCG LPS group and the non-hCG LPS group on the basis of whether they used hCG as LPS after blastocyst transfer. The primary outcome was the clinical pregnancy and live birth rates. The secondary outcomes included the early miscarriage rate (before 12 gestational week) and total miscarriage rate.
A total of 4762 women were included in the analysis, and 1910 received hCG LPS and 2852 received no hCG LPS (control group). In the general cohort, the clinical pregnancy and live birth rates in the hCG LPS group were significantly lower than those in the control group (63.82% vs 66.41%, aOR 0.872, 95% CI 0.765-0.996, =0.046; 53.98% vs 57.15%, aOR 0.873, 95% CI 0.766-0.991, =0.035, respectively). The early miscarriage and total miscarriage rates were similar between the two groups. In a subgroup analysis, in women who received an hCG trigger, there was no significant difference in the clinical pregnancy rate or live birth rate between the two groups. However, in women who ovulated spontaneously, the clinical pregnancy and live birth rates in the hCG LPS group were significantly lower than those in the control group (60.99% vs 67.21%, aOR 0.786, 95% CI 0.652-0.946, =0.011; 50.56% vs 57.63%, aOR 0.743, 95% CI 0.619-0.878, =0.001, respectively).
Among women undergoing natural cycle frozen-thawed blastocyst transfer, hCG LPS is associated with lower clinical pregnancy and live birth rates. Additionally, the adverse effect of hCG LPS is more pronounced in women who ovulate spontaneously.
在自然冻融胚胎移植(FET)周期中,黄体支持(LPS)的应用较为普遍,这主要是因为它对生殖结局有有益的影响。在各种 LPS 药物中,人绒毛膜促性腺激素(hCG)对黄体和子宫内膜都有作用。
评估 hCG 作为 LPS 在自然 FET 周期中的生殖结局中的作用。
本研究为回顾性队列分析,在一家三级保健医院进行。纳入 2018 年 1 月至 2022 年 12 月接受自然 FET 治疗的女性。根据囊胚移植后是否使用 hCG 作为 LPS,将患者分为 hCG LPS 组和非 hCG LPS 组。主要结局是临床妊娠率和活产率。次要结局包括早期流产率(12 孕周前)和总流产率。
共纳入 4762 名女性,其中 1910 名接受 hCG LPS,2852 名接受非 hCG LPS(对照组)。在一般队列中,hCG LPS 组的临床妊娠率和活产率明显低于对照组(63.82%比 66.41%,aOR 0.872,95%CI 0.765-0.996,=0.046;53.98%比 57.15%,aOR 0.873,95%CI 0.766-0.991,=0.035)。两组早期流产率和总流产率相似。亚组分析显示,在接受 hCG 扳机的女性中,两组临床妊娠率和活产率无显著差异。然而,在自然排卵的女性中,hCG LPS 组的临床妊娠率和活产率明显低于对照组(60.99%比 67.21%,aOR 0.786,95%CI 0.652-0.946,=0.011;50.56%比 57.63%,aOR 0.743,95%CI 0.619-0.878,=0.001)。
在自然周期冻融囊胚移植的女性中,hCG LPS 与较低的临床妊娠率和活产率相关。此外,hCG LPS 的不良作用在自然排卵的女性中更为明显。